News-Medical.Net on MSN
New antibody drug conjugates can transform early HER2-positive breast cancer treatment
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of ...
Elissa Kalver was 34 when she found a lump in her breast. She had no family history of cancer and had just welcomed her first child. She assumed the lump was a cyst. But when she went to get it ...
Roche has given two early-phase bispecifics the heave-ho, ending work on a HER2xCD3 prospect and an IL-15 candidate it picked up from Xencor. The drugmaker removed (PDF) the molecules from its phase 1 ...
EATON: A phase I trial of nazartinib (EGF816) and trametinib in EGFR-mutant (EGFRmut) non-small cell lung cancer (NSCLC). This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Circulating tumor DNA, pathologic response after neoadjuvant therapy, and survival: First results from TBCRC 040 (the PREDICT-DNA trial). This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback